Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC

Reuters04-01

Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC

Rigel reported final Phase 1/2 ARROW trial results for once-daily RET inhibitor Gavreto in metastatic RET fusion-positive NSCLC, published in Journal of Clinical Oncology, with added long-term follow-up versus earlier disclosures.
Study showed durable tumor responses across treated populations, supporting Gavreto positioning as a first-line option.
Data also indicated activity in patients with baseline central nervous system metastases, reinforcing potential use in broader real-world settings.
Safety profile remained manageable with no new safety signals, though treatment-related deaths were reported in a subset of treatment-naive patients in Asia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310805PR_NEWS_USPR_____SF23013) on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624555464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624555464","market":"fut","top_or_hot":-1,"title":"Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Rigel reported final Phase 1/2 ARROW trial results for once-daily RET inhibitor Gavreto in metastatic RET fusion-positive NSCLC, published in Journal of Clinical Oncology, with added long-term follow-up versus earlier disclosures.\n        </li>\n<li>\n          Study showed durable tumor responses across treated populations, supporting Gavreto positioning as a first-line option.\n        </li>\n<li>\n          Data also indicated activity in patients with baseline central nervous system metastases, reinforcing potential use in broader real-world settings.\n        </li>\n<li>\n          Safety profile remained manageable with no new safety signals, though treatment-related deaths were reported in a subset of treatment-naive patients in Asia.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RIGL\">Rigel Pharmaceuticals</a> Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310805PR_NEWS_USPR_____SF23013) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 05:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Rigel reported final Phase 1/2 ARROW trial results for once-daily RET inhibitor Gavreto in metastatic RET fusion-positive NSCLC, published in Journal of Clinical Oncology, with added long-term follow-up versus earlier disclosures.\n        </li>\n<li>\n          Study showed durable tumor responses across treated populations, supporting Gavreto positioning as a first-line option.\n        </li>\n<li>\n          Data also indicated activity in patients with baseline central nervous system metastases, reinforcing potential use in broader real-world settings.\n        </li>\n<li>\n          Safety profile remained manageable with no new safety signals, though treatment-related deaths were reported in a subset of treatment-naive patients in Asia.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RIGL\">Rigel Pharmaceuticals</a> Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310805PR_NEWS_USPR_____SF23013) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLtl5t4:1","article_id":"2624555464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624555464","pubTimestamp":1774993493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rigel reported final Phase 1/2 ARROW trial results for once-daily RET inhibitor Gavreto in metastatic RET fusion-positive NSCLC, published in Journal of Clinical Oncology, with added long-term follow-up versus earlier disclosures.Study showed durable tumor responses across treated populations, supporting Gavreto positioning as a first-line option.Data also indicated activity in patients with baseline central nervous system metastases, reinforcing potential use in broader real-world settings.Safety profile remained manageable with no new safety signals, though treatment-related deaths were reported in a subset of treatment-naive patients in Asia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RIGL":"Rigel Pharmaceuticals"},"translate_title":"Rigel表示最终ARROW数据显示GAVRETO治疗RET+NSCLC的缓解率为70%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RIGL":0.9},"content_text":"Rigel says final ARROW data show 70% response rate for GAVRETO in RET+ NSCLC\n    \n\n\n          Rigel reported final Phase 1/2 ARROW trial results for once-daily RET inhibitor Gavreto in metastatic RET fusion-positive NSCLC, published in Journal of Clinical Oncology, with added long-term follow-up versus earlier disclosures.\n        \n\n          Study showed durable tumor responses across treated populations, supporting Gavreto positioning as a first-line option.\n        \n\n          Data also indicated activity in patients with baseline central nervous system metastases, reinforcing potential use in broader real-world settings.\n        \n\n          Safety profile remained manageable with no new safety signals, though treatment-related deaths were reported in a subset of treatment-naive patients in Asia.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603310805PR_NEWS_USPR_____SF23013) on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624555464","isCrawlerRequest":true}